Key result
An NMR-based screen identified a biphenyl ether compound that inhibits the DNA binding of the HPV-E2 protein with an IC50 of approximately 10 microM, serving as a lead for antiviral development.
This is the authors' abstract. We don't add key points for this paper.
The E2 protein is required for the replication of human papillomaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas. Using an NMR-based screen, we tested compounds for binding to the DNA-binding domain of the HPV-E2 protein. Three classes of compounds were identified which bound to two distinct sites on the protein. Biphenyl and biphenyl ether compounds containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of E2 to DNA. Benzophenone-containing compounds which lack a carboxylic acid group bind to the beta-barrel formed by the dimer interface and exhibit negligible effects on the binding of E2 to DNA. Structure-activity relationships from the biphenyl and biphenyl ether compounds were combined to produce a compound [5-(3'-(3",5"-dichlorophenoxy)-phenyl)-2,4-pentadienoic acid] with an IC50 value of approximately 10 microM. This compound represents a useful lead for the development of antiviral agents that interfere with HPV replication and further illustrates the usefulness of the SAR by NMR method in the drug discovery process.
Answers are grounded in this paper and cite their sources.
The study identifies a lead compound that inhibits HPV E2 protein binding to DNA, providing a potential basis for developing antiviral agents against HPV.
No takes yet. Share an insight, caveat, or question.
Hajduk et al. (1997) studied Human papillomavirus (HPV). Biphenyl and biphenyl ether compounds (e.g., 5-(3'-(3",5"-dichlorophenoxy)-phenyl)-2,4-pentadienoic acid) was evaluated on Inhibition of E2 binding to DNA (IC50 ~10 microM). An NMR-based screen identified a biphenyl ether compound that inhibits the DNA binding of the HPV-E2 protein with an IC50 of approximately 10 microM, serving as a lead for antiviral development.
Synapse has enriched 10 related papers. Consider them for comparative context: